Unlike systemic chemotherapy for hematological malignancies with hepatitis B virus (HBV) infection, transarterial chemoembolization (TACE) for HBV-related hepatocellular carcinoma (HCC) has only recently been reported to cause HBV reactivation and subsequent hepatitis. Most patients with HBV-related HCC have an underlying disease with liver fibrosis or cirrhosis, and TACE may potentially induce HBV reactivation and liver decompensation. Currently, there are no clinical guidelines for managing TACE-caused HBV reactivation. In this review, we summarize the changes of HBV status and liver function after TACE and the effect of antiviral treatment before, during, or after TACE.
All Keywords
【저자키워드】 antiviral therapy, Liver function, Hepatitis B virus, Hepatocellular carcinoma, transarterial chemoembolization, HBV reactivation, Nucleotide/nucleoside analogues,
【저자키워드】 antiviral therapy, Liver function, Hepatitis B virus, Hepatocellular carcinoma, transarterial chemoembolization, HBV reactivation, Nucleotide/nucleoside analogues,